<?xml version="1.0" encoding="UTF-8"?>
<p>Due to the fact that the trifluoromethylated fused triazinones (
 <bold>Iâ€“VIII</bold>) showed significant pharmacological activities, selectivities as well as favourable pharmacokinetic properties, which have been recently patented
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0007" ref-type="bibr">
  <sup>7</sup>
 </xref> and published
 <xref rid="CIT0008" ref-type="bibr">
  <sup>8</sup>
 </xref>, they can be considered as valuable anticancer drug candidates in the preclinical phase of drug development. Therefore, it was necessary to extend studies on this class of molecules by assessing their toxicity profile in a modern vertebrate model as well as their proapoptotic action in caspase-based assays.
</p>
